HDT Bio’s self-replicating RNA (repRNA) vaccines harness the immune system to combat difficult-to-treat conditions and improve patient lives worldwide.
The AMPLIFY vaccine platform — The next generation of RNA vaccines
HDT’s RNA vaccine platform combines its self-amplifying RNA (“repRNA”) and LION™ technology to provide increased potency compared to traditional mRNA vaccines.

Latest News
MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
HDT Bio's LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ -- MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid...
Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
Click here to view article
Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines
Click here to view article